Oncolytic adenovirus, Survivin, Gene therapy

2 trials

Sponsors

Nagano Satoshi, Nagano Satoshi

Conditions

Advanced primary malignant bone tumor Bone tumor

Phase 2

Phase II trial of Survivin-responsive oncolytic adenovirus (Surv.m-CRA-1) by repeated intratumoral injection in advanced bone tumor patients.

Active, not recruitingJPRN-jRCT2073210118

Nagano SatoshiAdvanced primary malignant bone tumor Bone tumor

Start: 2022-01-22Target: 20Updated: 2026-06-29

Phase 3

A verification trial of survivin-responsive conditionally replicating adenovirus that targets and/or treats tumor cells with multiple factors-1 (Surv.m-CRA-1) by repeated intratumoral local administration in advanced malignant bone tumor patients.

Active, not recruitingJPRN-jRCT2073250100

Nagano SatoshiAdvanced primary malignant bone tumor Bone tumor

Start: 2025-11-25Target: 12Updated: 2026-06-29